Form 4: Phathom Pharmaceuticals COO Azmi Nabulsi Reports Stock and Option Awards

Azmi Nabulsi, Chief Operating Officer of Phathom Pharmaceuticals, reports the acquisition of restricted stock units and stock options.

Summary

• On February 27, 2025, Azmi Nabulsi, the Chief Operating Officer of Phathom Pharmaceuticals, acquired 79,200 restricted stock units (RSUs) and 55,000 stock options.
• The RSUs vest in three equal installments on the anniversaries of February 27, 2025.
• Each RSU represents the right to receive one share of Phathom Pharmaceuticals common stock.
• The stock options vest 25% on February 27, 2026, and the remainder in equal monthly installments over the following three years.
• The exercise price of the stock options is $5.76.
• Following these transactions, Nabulsi directly owns 312,590 shares of common stock, 3,578.93 shares indirectly through a 401(k), and 785,700 shares indirectly through a trust.
• Nabulsi also directly owns 55,000 stock options.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, indicating stability and alignment of interests. The sentiment is neutral to positive as it suggests the company is investing in its leadership.

Positives

• The grant of RSUs and stock options to the COO aligns his interests with those of the shareholders.
• The vesting schedules for the RSUs and stock options incentivize continued service to the company.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedules suggest an expectation of continued service by the reporting person.

Industry Context

Stock option and RSU grants are common forms of executive compensation in the pharmaceutical industry, used to attract and retain talent and align management interests with shareholder value.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are standard practice in the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize similar equity-based compensation to incentivize their executives.
• The vesting schedules and exercise prices are generally aligned with industry norms to ensure long-term commitment and performance.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning management's interests with the company's long-term success.
• Employees may see the grants as a sign of confidence in the company's future.

Key Dates